<DOC>
	<DOCNO>NCT00882206</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop growth cancer cell , either kill cell stop dividing . Decitabine vorinostat may alter cancer cell reverse cancer pathway need cell growth . Giving one drug ( combination chemotherapy ) together decitabine vorinostat may kill cancer cell chemotherapy alone . PURPOSE : This phase II trial study well give decitabine vorinostat together combination chemotherapy work treat patient acute lymphoblastic leukemia lymphoblastic lymphoma relapse responded treatment .</brief_summary>
	<brief_title>Pre-reinductive Decitabine Vorinostat Relapsed Lymphoblastic Lymphoma Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : Primary - Patients undergo blood bone marrow sample collection baseline , day 5 , Day 19 end study treatment correlative laboratory study . Samples analyze hypermethylation diagnosis demethylation post-exposure decitabine vorinostat use LINE methylation . OUTLINE : Patients receive decitabine IV 1 hour oral vorinostat twice daily day 1-4 ; vincristine sulfate IV day 5 , 12 , 19 , 26 ; oral prednisone twice daily day 5-33 ; doxorubicin hydrochloride IV 15 minute cytarabine intrathecally ( IT ) day 5 ; pegaspargase IV intramuscularly day 6 , 12 , 19 , 26 ; methotrexate* IT day 12 33 . Patients Philadelphia chromosome-positive disease may also receive oral imatinib mesylate daily day 5-33 . NOTE : *Patients central nervous system ( CNS ) -positive disease also receive methotrexate IT day 19 26 . Patients undergo blood bone marrow sample collection baseline , day 5 , Day 19 end study treatment correlative laboratory study . After completion study treatment , patient follow 60 day .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Diagnosis lymphoblastic lymphoma acute lymphoblastic leukemia ≥ 5 % blast bone marrow ( M2/M3 ) ( without extramedullary disease ) meet 1 follow criterion : Refractory disease/induction failure ( failure achieve initial remission 2 line induction therapy ) Relapsed disease ( first relapse high ) Central nervous system ( CNS ) positive disease allow Karnofsky performance status ( PS ) 50100 % ( patient ≥ 16 year age ) OR Lansky PS 50100 % ( patient &lt; 16 year age ) Life expectancy ≥ 8 week Creatinine clearance ≥ 70 mL/min OR maximum serum creatinine base age/gender follow : 0.4 mg/dL ( patient 1 5 month age ) 0.5 mg/dL ( patient 6 11 month age ) 0.6 mg/dL ( patient 1 year age ) 0.8 mg/dL ( patient 2 5 year age ) 1.0 mg/dL ( patient 6 9 year age ) 1.2 mg/dL ( patient 10 12 year age ) 1.5 mg/dL ( male ) 1.4 mg/dL ( female ) ( patient 13 15 year age ) 1.7 mg/dL ( male ) 1.4 mg/dL ( female ) ( patient ≥ 16 year age ) ALT &lt; 5 time upper limit normal ( ULN ) Total bilirubin ≤ 1.5 time ULN age LVEF ≥ 40 % ECHO/MUGA scan Shortening fraction &gt; 29 % ECHO/MUGA scan Able swallow capsule Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 2 month completion study treatment No untreated positive blood culture progressive infection assess radiographic study No known allergy agent ingredient use study Patients clinically significant prior allergy pegaspargase may treat asparaginaseErwinia , available Patients receive asparaginase study ( e.g. , due prior pancreatitis , stroke , toxicity ) eligible provide meet inclusion/exclusion criterion Recovered prior therapy ( define CTCAE v3.0 toxicity ≤ grade 1 ) More 3 week since prior chemotherapy cancer hydroxyurea patient WBC &gt; 10,000/mm³ At least 7 day since prior hematopoietic growth factor ( 14 day pegfilgrastim ) At least 1 month since prior biologic therapy , monoclonal antibody At least 3 month since prior hematopoietic stem cell transplantation Evidence graftversushost disease Concurrent valproic acid Concurrent coumadin/warfarin short course administer prophylactic setting</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
</DOC>